U.S. markets closed

ProKidney Corp. (PROK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5100+0.0100 (+0.67%)
At close: 04:00PM EST
1.5019 -0.01 (-0.54%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close1.5000
Bid1.5000 x 1400
Ask1.6800 x 1800
Day's Range1.5000 - 1.5500
52 Week Range1.1200 - 14.1900
Avg. Volume606,209
Market Cap1.812B
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.5800
Earnings DateMar 04, 2024 - Mar 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PROK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ProKidney Corp.
    SHC: Raising target price to $17.00SOTERA HEALTH CO has an Investment Rating of HOLD; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
  • Insider Monkey

    Chamath Palihapitiya Stocks: 12 Stocks Pumped in the Last 10 Years

    In this article, we discuss Chamath Palihapitiya and the 12 stocks he pumped in the last 10 years. If you want to read about some more Chamath Palihapitiya stocks, go directly to Chamath Palihapitiya Stocks: 5 Stocks Pumped in the Last 10 Years. Chamath Palihapitiya is an investing genius, even though some of his opinions […]

  • Zacks

    Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now

    ProKidney Corp. (PROK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

  • GlobeNewswire

    ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer

    Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidneyWINSTON-SALEM, N.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Nikhil Pereira-Kamath, MBA, Vice President of Business Development & Innovative Solutions, to Chief Business Officer (CBO). As CBO, Nikhil will have global respon